Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011829 · ClinicalTrials.gov registry record · Phase 2
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
A Phase 2 study of Substance Abuse and Methamphetamine-dependence, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01011829 is a Phase 2 study of Substance Abuse and Methamphetamine-dependence that has completed, run by University of California, Los Angeles. The registered enrollment target is 20 participants, below the 5,260-participant average among 58 other Substance Abuse trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01011829, a Phase 2 study of Substance Abuse and Methamphetamine-dependence, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Methamphetamine (MA) abuse is the fastest growing drug problem in the United States and is responsible for significant public health complications, including HIV infection. As a result effective treatments for MA dependence are urgently needed. There are currently no efficacious medications for MA dependence, although results from preliminary randomized trials of bupropion for MA dependence found bupropion to be more effective than placebo, but only among subgroups of participants, including those with lower frequency of MA use at baseline. A growing body of preclinical and clinical studies suggest that cholinergic mechanisms play an important role in the neurobiology of MA and other stimulant dependence, such as nicotine dependence. Mechanistically, cholinergic medications may alleviate MA-associated cognitive dysfunction, thereby improving outcomes of treatment for MA dependence. Varenicline is a partial agonist at α4β2 nicotinic receptors and a full agonist at α7 nicotinic receptors that has been approved as an anti-cigarette smoking medication. In order to assess the potential efficacy of varenicline for methamphetamine dependence, we will perform a clinical trial to assess if varenicline compared to placebo results in greater: 1. reductions in methamphetamine use; 2. treatment retention;
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
Study Locations (1)
California
- UCLA Vine Street Clinic - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011829
The ClinicalTrials.gov registry entry for NCT01011829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,260-participant average among 58 other Substance Abuse trials with a reported enrollment target (100% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Substance Abuse appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01011829 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01011829 about?
NCT01011829 is a clinical study titled "Varenicline vs Placebo for the Treatment of Methamphetamine Dependence". Methamphetamine (MA) abuse is the fastest growing drug problem in the United States and is responsible for significant public health complications, including HIV infection. As a result effective treatments for MA dependence are urgently needed. There are currently no efficacious medications for MA d...
What is the current status of trial NCT01011829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2009-11. Estimated completion is 2010-05.
What conditions does trial NCT01011829 study?
This clinical trial studies the following conditions: Substance Abuse, Methamphetamine-dependence, Methamphetamine Abuse.
What interventions are being tested in trial NCT01011829?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT01011829?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01011829 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes
COMPLETED · Phase 2
-
Evaluation of Treatments for Homeless Youths
COMPLETED · Phase 2
-
Substance Treatment and HIV Testing and Referral System
COMPLETED · Phase 2
-
Study of Medical Treatment for Methamphetamine Addiction
COMPLETED · Phase 2
-
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
COMPLETED · Phase 2
-
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.